Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

October 31, 2009

Conditions
Pulmonary FibrosisHypertension, Pulmonary
Interventions
DRUG

Sildenafil Citrate

Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)

OTHER

Placebo

Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)

Trial Locations (13)

10021

Weill Medical College of Cornell University, New York

27710

Duke University Medical Center, Durham

30322

Emory University, Atlanta

35294

University of Alabama - Birmingham, Birmingham

37232

Vanderbilt University, Nashville

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

70118

Tulane University, New Orleans

80206

National Jewish Medical and Research Center, Denver

90095

University of California - Los Angeles, Los Angeles

94110

University of California - San Francisco, San Francisco

98165

University of Washington, Seattle

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Pfizer

INDUSTRY

lead

Duke University

OTHER

NCT00517933 - Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter